Real-world Study of Anlotinib Capsules for Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

What this Trial Is About

Researchers are investigating the use of Anlotinib capsules for patients with locally advanced or metastatic differentiated thyroid cancer that no longer responds to radioactive iodine treatment. This real-world study aims to evaluate how well Anlotinib works and its safety in a broad patient population over time. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group and includes patients aged 18 to 75 years. Participants receiving Anlotinib will take 12 mg of the capsules once daily for two weeks, followed by a one-week break, in repeating 21-day cycles. Another group will be observed and their data collected without receiving Anlotinib or similar small-molecule antivascular drugs. The study will continue to collect data prospectively and retrospectively, comparing outcomes between those treated with Anlotinib and those who are not. During the study, researchers will monitor participants for up to three years, assessing measures such as overall response rate, progression-free survival, disease control rate, duration of response, overall survival, and adverse events. Data collection will include medical evaluations, imaging, and laboratory tests to understand treatment effects and safety. Participants will be closely followed throughout the study to document their health and treatment experiences.

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma